Literature DB >> 16673675

Framework for describing and classifying decision-making systems using technology assessment to determine the reimbursement of health technologies (fourth hurdle systems).

John Hutton1, Clare McGrath, Jean-Marc Frybourg, Mike Tremblay, Edward Bramley-Harker, Christopher Henshall.   

Abstract

OBJECTIVES: Australia, Canada, and many European countries now use various forms of health technology assessment (HTA) in decision making regarding the reimbursement of drugs and other health technologies. To achieve a better understanding of the potential for use of HTA in this context, an analytical framework was developed to describe and classify existing fourth hurdle systems.
METHODS: Based on a review of published literature, and official documentation, the key aspects of a fourth hurdle system were identified at two levels: policy implementation and individual technology decision. Characteristics of the systems were grouped under four main headings: constitution and governance, objectives, use of evidence and decision processes, and accountability. The comprehensiveness and relevance of this framework was assessed by an independent group of experts in HTA. A pilot study was undertaken, using only published sources, to test the feasibility of obtaining the information needed to complete the framework.
RESULTS: The framework was found to be sufficiently broad to encompass all the issues of interest regarding the systems, but the proportion of information available from published sources was variable between sections of the framework and between countries, with average availability of 45 percent.
CONCLUSIONS: The analytical framework will help researchers and policy makers in individual countries to understand their own systems and will allow some preliminary sharing of experience between countries. More experience of its application is needed to judge whether it will provide the basis for more formal comparison of systems and whether it will determine their appropriateness for particular decision contexts.

Mesh:

Year:  2006        PMID: 16673675     DOI: 10.1017/s0266462306050781

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  15 in total

1.  Analysing coverage decision-making: opening Pandora's box?

Authors:  Katharina Elisabeth Fischer; Reiner Leidl
Journal:  Eur J Health Econ       Date:  2014-02-06

2.  What values do the public want their health care systems to use in evaluating technologies?

Authors:  Martin J Buxton; James D Chambers
Journal:  Eur J Health Econ       Date:  2011-08

Review 3.  Funding decisions for newborn screening: a comparative review of 22 decision processes in Europe.

Authors:  Katharina Elisabeth Fischer; Wolf Henning Rogowski
Journal:  Int J Environ Res Public Health       Date:  2014-05-19       Impact factor: 3.390

4.  Decision-making in healthcare: a practical application of partial least square path modelling to coverage of newborn screening programmes.

Authors:  Katharina E Fischer
Journal:  BMC Med Inform Decis Mak       Date:  2012-08-02       Impact factor: 2.796

5.  The use of continuous data versus binary data in MTC models: a case study in rheumatoid arthritis.

Authors:  Susanne Schmitz; Roisin Adams; Cathal Walsh
Journal:  BMC Med Res Methodol       Date:  2012-11-06       Impact factor: 4.615

Review 6.  When are statins cost-effective in cardiovascular prevention? A systematic review of sponsorship bias and conclusions in economic evaluations of statins.

Authors:  Ferrán Catalá-López; Gabriel Sanfélix-Gimeno; Manuel Ridao; Salvador Peiró
Journal:  PLoS One       Date:  2013-07-08       Impact factor: 3.240

7.  Clearing up the hazy road from bench to bedside: a framework for integrating the fourth hurdle into translational medicine.

Authors:  Wolf H Rogowski; Susanne C Hartz; Jürgen H John
Journal:  BMC Health Serv Res       Date:  2008-09-24       Impact factor: 2.655

8.  From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries.

Authors:  Dimitra Panteli; Helene Eckhardt; Alexandra Nolting; Reinhard Busse; Michael Kulig
Journal:  Health Res Policy Syst       Date:  2015-09-25

9.  Reimbursement of orphan drugs in Belgium: what (else) matters?

Authors:  Eline Picavet; David Cassiman; Steven Simoens
Journal:  Orphanet J Rare Dis       Date:  2014-09-12       Impact factor: 4.123

Review 10.  Evidence for Health III: Making evidence-informed decisions that integrate values and context.

Authors:  Anne Andermann; Tikki Pang; John N Newton; Adrian Davis; Ulysses Panisset
Journal:  Health Res Policy Syst       Date:  2016-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.